How should hyperosmolar hyperglycemic state be managed in a patient with reduced ejection fraction and congestive heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Hyperosmolar Hyperglycemic State in Patients with Reduced Ejection Fraction and Heart Failure

In patients with HHS and reduced ejection fraction heart failure, fluid resuscitation must be significantly more cautious than standard HHS protocols, with initial 0.9% saline at reduced rates (500-750 mL/h rather than 1-1.5 L/h), close hemodynamic monitoring in an ICU setting, and early consideration of insulin therapy to minimize total fluid requirements while maintaining guideline-directed medical therapy for heart failure throughout the acute episode.

Critical Modifications to Standard HHS Management

Fluid Resuscitation Strategy

The primary challenge in managing HHS with reduced ejection fraction is balancing the severe dehydration characteristic of HHS against the limited cardiac reserve and propensity for pulmonary edema in heart failure patients.

Standard HHS protocols recommend aggressive fluid replacement:

  • ADA guidelines suggest 15-20 mL/kg/h or 1-1.5 L/h of 0.9% saline initially 1
  • JBDS guidelines recommend replacing ~50% of estimated fluid loss within 12 hours 1
  • Total fluid deficits in HHS typically range 8-12 liters 2

In patients with reduced ejection fraction, modify this approach:

  • Start with 0.9% saline at 500-750 mL/h (approximately half the standard rate)
  • Monitor for signs of volume overload continuously: respiratory rate, oxygen saturation, lung auscultation, jugular venous pressure
  • Consider point-of-care ultrasound to assess inferior vena cava diameter and lung B-lines to guide fluid administration 3
  • Transition to 0.45% saline once hemodynamically stable, but maintain slower infusion rates than standard protocols
  • Target osmolality correction <3 mOsm/kg/h to allow more gradual rehydration 1

Insulin Therapy Approach

Prioritize earlier insulin initiation in heart failure patients to reduce total fluid requirements by accelerating glucose correction:

  • Administer 10-15 units regular insulin IV bolus followed by 0.05-0.1 units/kg/h infusion 2, 1
  • The lower insulin infusion rate (0.05 units/kg/h per JBDS) may be preferable initially to allow more controlled fluid shifts 1
  • Once glucose approaches 13.9-16.7 mmol/L (250-300 mg/dL), add 5% dextrose to IV fluids and reduce insulin rate 2
  • This strategy minimizes osmotic diuresis duration and total volume requirements

Electrolyte Management Considerations

Potassium replacement requires heightened vigilance:

  • Patients with HFrEF are commonly on RAAS inhibitors and mineralocorticoid receptor antagonists, increasing baseline hyperkalemia risk 4
  • Monitor potassium every 2-4 hours during acute management
  • Replace potassium cautiously when <4.5 mEq/L, but avoid aggressive replacement that could precipitate dangerous hyperkalemia
  • Consider temporarily holding MRAs during acute HHS but maintain other heart failure medications if hemodynamically tolerated

Continuation of Heart Failure Medications

Maintain guideline-directed medical therapy throughout HHS management whenever possible:

The foundational medications for HFrEF include ACE inhibitors/ARNIs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors 5, 4. During acute HHS:

  • Continue beta-blockers unless severe hypotension or cardiogenic shock develops. Carvedilol is particularly appropriate as it is poorly dialyzed and associated with cardiovascular benefit 6
  • Continue SGLT2 inhibitors if already prescribed, as they improve outcomes across the HFrEF spectrum and do not significantly worsen dehydration once fluid resuscitation is initiated 5, 4
  • Temporarily hold or reduce ACE inhibitors/ARNIs if significant hypotension present, but resume as soon as blood pressure stabilizes
  • Temporarily hold MRAs during the acute phase due to hyperkalemia risk, but resume once electrolytes normalize 4

Misinterpretation of transient kidney function changes is a leading cause of inappropriate discontinuation of heart failure medications 4. Small increases in creatinine during HHS treatment should not automatically trigger medication cessation.

Monitoring and Setting

All patients with HHS and reduced ejection fraction require ICU-level care 7:

  • Continuous cardiac monitoring
  • Hourly vital signs and fluid balance
  • Laboratory monitoring every 2-4 hours initially: glucose, electrolytes, osmolality, renal function
  • Frequent clinical assessment for volume overload: lung examination, oxygen requirements, work of breathing
  • Consider invasive hemodynamic monitoring if clinical assessment is unclear or patient deteriorates

Common Pitfalls to Avoid

  1. Over-aggressive fluid resuscitation: The standard HHS fluid rates will precipitate acute pulmonary edema in most patients with significantly reduced ejection fraction. Start slower and titrate based on clinical response.

  2. Discontinuing all heart failure medications: While some temporary adjustments are necessary, wholesale discontinuation worsens long-term outcomes and makes reinitiation more difficult 4.

  3. Inadequate monitoring intensity: These patients require more intensive monitoring than either condition alone. Standard ward-level care is insufficient.

  4. Delayed insulin therapy: Waiting too long to start insulin prolongs osmotic diuresis and increases total fluid requirements, compounding heart failure risk.

  5. Ignoring precipitating causes: Cardiovascular disease and infections are the most common HHS triggers 7. Acute coronary syndrome, heart failure exacerbation, or infection must be identified and treated concurrently.

Prognosis and Post-Acute Management

HHS carries high mortality (15-20%), which is further elevated in patients with heart failure 7, 1. Following recovery:

  • Many patients will not require long-term insulin and can be managed with oral agents or diet 2
  • Ensure full reinitiation and optimization of guideline-directed medical therapy for heart failure
  • Address precipitating factors to prevent recurrence
  • Close outpatient follow-up within 1-2 weeks to reassess volume status, electrolytes, and medication tolerance

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.